Cysteinyl leukotrienes in allergic inflammation - Strategic target for therapy

被引：110

作者：

Busse, W

Kraft, M

机构：

[1] Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53792 USA

[2] Natl Jewish Med & Res Ctr, Denver, CO USA

来源：

CHEST | 2005年 / 127卷 / 04期

关键词：

asthma; cytokines; eosinophils; inflammation; leukotrienes; leukotriene receptor antagonists; remodeling; rhinitis;

D O I：

10.1378/chest.127.4.1312

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

Systemically bioavailable leukotriene receptor antagonists (LTRAs) can reduce the essential components of allergic inflammation in allergic rhinitis (AR) and asthma by blocking cysteinyl leukotriene (CysLT) activity, resulting in a wide range of clinical effects. CysLTs, mediators, and modulators in the pathophysiology of asthma and AR are a key target for therapy because they modulate production of hemopoietic progenitor cells, survival and recruitment of eosinophils to inflamed tissue, activity of cytokines and chemokines, quantity of exhaled NO, smooth-muscle contraction, and proliferation of fibroblasts. The mechanism of action of LTRAs leads to their effects on systemic allergic inflammatory processes.

引用

收藏

页码：1312 / 1326

页数：15

相关论文

共 115 条

[31] RECOVERY OF LEUKOTRIENE-E4 FROM THE URINE OF PATIENTS WITH AIRWAY-OBSTRUCTION [J].

DRAZEN, JM ;

OBRIEN, J ;

SPARROW, D ;

WEISS, ST ;

MARTINS, MA ;

ISRAEL, E ;

FANTA, CH .

AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 146 (01) :104-108

[32]

Evans J., 2001, Clinical and Experimental Allergy Reviews, V1, P142, DOI 10.1046/j.1472-9725.2001.00026.x

[33]

Ferreira M B, 2001, Allerg Immunol (Paris), V33, P315

[34] Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytes [J].

Figueroa, DJ ;

Breyer, RM ;

Defoe, SK ;

Kargman, S ;

Daugherty, BL ;

Waldburger, K ;

Liu, QY ;

Clements, M ;

Zeng, ZZ ;

O'Neill, GP ;

Jones, TR ;

Lynch, KR ;

Austin, CP ;

Evans, JF .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2001, 163 (01) :226-233

[35] Zafirlukast for symptomatic mild-to-moderate asthma: A 13-week multicenter study [J].

Fish, JE ;

Kemp, JP ;

Lockey, RF ;

Glass, M ;

Hanby, LA ;

Bonuccelli, CM ;

Bronsky, E ;

Condemi, J ;

Goldstein, S ;

Norton, J ;

Rosenthal, R ;

Silvers, W ;

Tinkelman, D ;

Weisberg, S ;

Winder, J .

CLINICAL THERAPEUTICS, 1997, 19 (04) :675-690

[36] Cysteinyl leukotrienes induce human eosinophil locomotion and adhesion molecule expression via a CysLT1 receptor-mediated mechanism [J].

Fregonese, L ;

Silvestri, M ;

Sabatini, F ;

Rossi, GA .

CLINICAL AND EXPERIMENTAL ALLERGY, 2002, 32 (05) :745-750

[37]

Gaga M, 2000, CLIN EXP ALLERGY, V30, P663

[38] Co-existence of asthma and allergic rhinitis: A 23-year follow-up study of college students [J].

Greisner, WA ;

Settipane, RJ ;

Settipane, GA .

ALLERGY AND ASTHMA PROCEEDINGS, 1998, 19 (04) :185-188

[39] Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects [J].

Hamilton, A ;

Faiferman, I ;

Stober, P ;

Watson, RM ;

O'Byrne, PM .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 102 (02) :177-183

[40] CYSTEINYL LEUKOTRIENES IN ASTHMA - OLD MEDIATORS UP TO NEW TRICKS [J].

HAY, DWP ;

TORPHY, TJ ;

UNDEM, BJ .

TRENDS IN PHARMACOLOGICAL SCIENCES, 1995, 16 (09) :304-309

← 1 2 3 4 5 6 7 8 9 10 →